Inactive Instrument

News Viracta Therapeutics, Inc. Nasdaq

Equities

US92765F1084

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma	Apr. 15	AQ
Viracta Therapeutics : HST 2024 – Presentation	Apr. 15	PU
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	Apr. 01	AQ
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	Apr. 01	CI
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	Mar. 21	MT
Viracta Therapeutics, Inc. Announces Executive Changes	Mar. 20	CI
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	Mar. 20	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Sunesis: Q4 Earnings Snapshot	Mar. 07	AQ
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 07	AQ
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial	Feb. 29	AQ
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
Viracta Therapeutics, Inc. Provides Clinical Update	Jan. 04	CI
Viracta Therapeutics Provides Clinical Update and Outlook for 2024	Jan. 04	AQ
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma	Dec. 12	AQ
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels	Dec. 04	AQ
Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels	Dec. 04	CI
RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	Nov. 10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Viracta Therapeutics, Inc. Nasdaq

Equities

US92765F1084

Summary

Filters